BioCentury | Apr 1, 2019
Clinical News

MSKCC CAR T shows 72% response in mesothelioma

...with its autologous CART-meso product, but has not reported any PRs or CRs. The UPenn CART-meso...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...MB-101 Brain cancer Ph I Mesothelin University of Pennsylvania / Novartis AG (NYSE:NVS; SIX:NOVN) CAR-T-Meso (cart-meso...
BioCentury | Sep 9, 2017

Some of the parts

...CAR Ts in clinical testing for solid tumors: CAR-T-EGFRvIII to treat glioblastoma multiforme (GBM) and CAR-T-Meso...
BioCentury | Jun 23, 2017
Emerging Company Profile

TRuCs vs. CARs

...therapy with a human anti-mesothelin binding domain, in Phase I for solid tumors. In 2015, CAR-T-meso...
BioCentury | Sep 19, 2016
Emerging Company Profile

Solid CARs

...were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso...
BioCentury | Apr 27, 2015
Product Development

CAR window

...some of the first data presented for a CAR T therapy in solid tumors - CART-meso...
BioCentury | Apr 27, 2015

CAR talk

...investors digested some of the first solid tumor data for a CAR T program - CART-meso... solid tumors," said individual investor Brad Loncar of Loncar Investments. "A big disappointment was CART-meso...
BioCentury | Apr 27, 2015
Clinical News

CAR-T-meso: Phase I data

...mesothelin-expressing tumors in a U.S. Phase I trial showed that a single infusion of 1-3*107 CAR-T-meso... another by radiological and clinical evidence of stable to decreased burden of disease. Furthermore, CAR-T-meso...
...2012). Novartis A G (NYSE:NVS; SIX:NOVN), Basel, Switzerland University of Pennsylvania , Philadelphia, Pa. Product: CAR-T-meso...
BioCentury | Apr 22, 2015
Company News

MaxCyte, JHU partner for preclinical CARs

...Cancer Research meeting in Philadelphia showed no complete or partial responders among five patients receiving CART-meso...
BioCentury | Apr 21, 2015
Top Story

CAR T stocks fall on solid tumor data

...meeting in Philadelphia on Sunday showed no complete or partial responders among five patients receiving CART-meso...
...response rates. Solid tumors create their own microenvironment and are heterogeneous and structurally complex. The CART-meso...
Items per page:
1 - 10 of 10